Senn Chemicals
– your CDMO

for SWISS quality peptides and amino acid derivatives

Vist our website

Email us

  • Specialized in peptide synthesis
  • Certified cGMP (manufacturing license Swissmedic, ISO 9001:2015)
  • Independent, family-owned, since 1963
  • Pre-clinical to commercial cGMP supply
  • Solution phase synthesis up to 2’500 L
  • Fmoc solid phase technology incl. prep HPLC and lyophilization
  • Fmoc, Boc, CbZ protected amino acid derivatives
  • From grams to metric ton scale
  • Starting materials, key intermediates and APIs

Senn – your partner in peptide chemistry

PASSION & CREATIVITY

Solution and solid phase synthesis Peptides and amino acid derivatives From R&D to commercial cGMP Grams to metric tons

TOP SWISS QUALITY

From early research to commercial phase

Go to article: Home | The Dawn of Big DataGo to article: EditorialGo to article: Scandinavian Health Ltd. Company InsightGo to article: Scandinavian Health Ltd.Go to article: ContentsGo to article: Daiichi JitsugyoGo to article: How will Amazon's acquisition of online pharmacy business PillPack disrupt the pharmaceutical industry? Go to article: HOF Sonderanlagenbau Company InsightGo to article: HOF SonderanlagenbauGo to article: Fentanyl: where did it all go wrong?Go to article: NSFGo to article: Komtur Pharmaceuticals Company InsightGo to article: Komtur PharmaceuticalsGo to article: Turning up the heat on nano researchGo to article: TSS Company InsightGo to article: TSS ABGo to article: MedelpharmGo to article: Cracking the mystery of Alzheimer's diseaseGo to article: Röchling Medical NeuhausGo to article: International Cannabis and Cannabinoid Institute (ICCI) Company InsightGo to article: International Cannabis and Cannabinoid Institute (ICCI)Go to article: Where are the world's pharma manufacturing hotspots?Go to article: Gerteis Company InsightGo to article: GerteisGo to article: ZenatekGo to article: How India’s use of unapproved antibiotics could undermine global healthGo to article: Novo Nordisk PharmatechGo to article: Phoenix Company InsightGo to article: PhoenixGo to article: CRISPR: a seismic shift in gene editingGo to article: CBDepot Company InsightGo to article: CBDepotGo to article: Is the UK’s drug evaluation system in need of an overhaul?Go to article: Nelson Labs Company InsightGo to article: Nelson LabsGo to article: Centaur Clinical | Company InsightGo to article: Centaur ClinicalGo to article: Opening up the Chinese drug marketGo to article: Finnair Cargo | Company InsightGo to article: Finnair CargoGo to article: Immunising against opioids – could a vaccine solve the crisis? Go to article: Molnar Company InsightGo to article: MolnarGo to article: PharmasolGo to article: The next generation of antimalarials Go to article: Oncology Therapeutic Development Company InsightGo to article: Oncology Therapeutic DevelopmentGo to article: Pharma Support Services Company InsightGo to article: Pharma Support ServicesGo to article: The People vs Big Pharma: tackling the industry’s trust issuesGo to article: G.F.Go to article: Pfanstiehl Company InsightGo to article: PfanstiehlGo to article: Amazon and PillPack: an unstoppable pharmacy force?Go to article: BEAGo to article: Buchi Labortechnik AG Company InsightGo to article: Buchi Labortechnik AGGo to article: Is the microbiome as important for precision medicine as genetics?Go to article: Medical HempGo to article: Senn ChemicalsGo to article: Senn ChemicalsGo to article: Niconex Medical LtdGo to article: HPV vaccines: a decade of progressGo to article: Med-Script AssociatesGo to article: B&W Tek | Company InsightGo to article: B&W TekGo to article: EventsGo to article: CG ChemikalienGo to article: AlpexGo to article: Next issueGo to article: Pall Biotech Company InsightGo to article: CrewpharmGo to article: EndocaGo to article: Diversey